Navigation Links
Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
Date:11/12/2012

CRANBURY, N.J., Nov. 12, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012, at 10:30 a.m. Eastern Time.  The conference will be held at The Pierre Hotel, New York City.

Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... ... SmartArch — a revolutionary new archwire that allows orthodontists to simultaneously apply different ... of the efficacy of SmartArch. “We’re thrilled about taking SmartArch one step closer ...
(Date:6/29/2015)... ... June 30, 2015 , ... This cutting edge standard making is a ... 12 distinct peaks, the WAV-8 is the world’s first cuvette-shaped, solid-state filter that lets ... the NIR range. Previous spectrophotometer calibration standards, such as those made from didymium glass ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... the terms of the agreement, MediVet will acquire the rights to a portfolio ... is currently in pre-clinical development as a potential next-generation treatment for various musculoskeletal ...
(Date:6/29/2015)... -- BioNano Genomics, Inc., the leader in genome mapping, ... that a collaboration led by the Icahn School of ... the first comprehensive analysis of a diploid human genome ... and genome mapping. This study, published today in ... contiguous diploid human genome assembly obtained without using inference-based ...
Breaking Biology Technology:New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3
... Citing one-time gains due to Hurricane Katrina and other Gulf ... a net loss of nearly $45 million, or 20 cents ... information management services firm reported net income of $105.9 million, ... of 2005, a drop of 29.6 percent. , ,The decrease ...
... visit to the Menomonee Valley, Gov. Jim Doyle ... state budget for the new Wisconsin Venture Center. , ,Doyle ... that will connect entrepreneurs with sources of capital, and serve ... in Wisconsin. , ,The concept was announced in December of ...
... most spending proposals, the devil is in the details and ... Jim Doyle's new Grow Milwaukee package contains several initiatives ... ,The package, which Doyle alluded to in last week's ... economic development, healthcare, and education proposals designed to build on ...
Cached Biology Technology:Doyle proposes $2M for venture capital center 2Grow Milwaukee includes millions for tech funding 2Grow Milwaukee includes millions for tech funding 3
(Date:6/24/2015)... -- The biologics safety testing market is growing at ... include growth of the pharmaceutical and biological industries and ... years, the number of drug approvals in North American ... approved 225 drug applications and Health Canada approved 99. ... accounted for 3,822 of the pharmaceutical and 1,998 ...
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... a 12-year action plan calling for reducing the hypoxia zone ... and there is no evidence that nutrient loading to the ... have identified some of the biophysical and social barriers to ... that a partnership of researchers work closely with farmers to ...
... N.H. A grant to the University of New ... biologists identify an abundant yet largely unknown category of ... functions they play. The National Science Foundation awarded ... Network on eukaryotic biodiversity. The work will apply new ...
... Md. (Nov. 7, 2013)Chronic obstructive pulmonary diseasea health problem ... it progressively harder to breathecan have a dramatic effect ... activities of daily life because of the disease,s fallout ... in these muscle problems. These include loss of fitness ...
Cached Biology News:Researchers suggest plan to address hypoxia in Gulf of Mexico 2Researchers suggest plan to address hypoxia in Gulf of Mexico 3UNH, UC Davis launch network to study environmental microbes 2Vitamin C could ease muscle fatigue in chronic obstructive pulmonary disease patients 2
... S-X media are neutral, porous ... exclusion chromatography of lipophilic polymers ... organic eluents. The beads are ... carbon tetrachloride, dimethylformamide, ketones, aromatics, ...
... Anti-GSTM1 Monoclonal Antibody Epitope: ... [Schistosoma japonicum]. Recommended Storage: ... Aliquot contents and freeze at -20 C ... of freezing and thawing. Centrifuge product if ...
Mouse monoclonal [HYB 232-02] to Protein S ( Abpromise for all tested applications). entrezGeneID: 5627 SwissProtID: P07225...
... unique aptamer microarray services using a ... and sequence design software to suit ... screening of aptamers as drug candidates. ... sequence design, synthesis of standard or ...
Biology Products: